Top biotech stocks preferred by hedge funds
Several biotech stocks in small-cap space didn’t see the kind of year which was expected from them by Wall Street analysts heading into 2023 however. RBC Capital Markets, a global investment management firm, anticipated that more permissive regulatory environment for drug approvals should result in top biotech stocks outperforming the market in 2023. This optimism